This was effective in preclinical models, in which the addition of programmed death-1 (PD-1)/PD-L1 inhibitors to RT reshaped the tumor microenvironment, boosting MHC-II+ dendritic cells and CD8+ T-cell infiltration while reducing Tregs and immunosuppressive cytokines [6]. Here, CD8A is linked to neoplasm.